Rabeprazole effects of gastroesophageal reflux disease with omeprazole compared.doc

 PAGE \* MERGEFORMAT 8 Rabeprazole effects of gastroesophageal reflux disease with omeprazole compared OF: Andrew Chuang thin trees the former Soviet Liu Yuan Yuan Road [Keywords:] rabeprazole, omeprazole, gastroesophageal reflux disease Gastroesophageal reflux disease (GERD is a common digestive disease, recurrent reflux disease can develop into Barrett esophagus and esophageal adenocarcinoma. Long-term use of proton pump inhibitor (PPI) can be effectively healed reflux disease mucosal damage, blocking the development of esophagitis to Barrett esophagus, thereby reducing the incidence of esophageal adenocarcinoma [1,2]. of September 2006 to February 2007 the application of new proton pump inhibitor rabeprazole (goods Mingruibote, treatment of GERD 34 cases, and earlier application of omeprazole (trade Mingao Ke, treatment of GERD 32 cases, compared two groups, are as follows. 1 Subjects and methods 1.1 disease cases 66 cases to our hospital from September 2006 to February 2007 out-patients, 44 males and 22 females, aged 19 to 62 years, average 42.3 years of age, clinical manifestations of heartburn, 58 patients (87.9%, acid reflux 52 patients (78.8%, chest pain in 43 cases (65.2%, belching 34 cases (51.5%; accompanied by hiatal hernia in 7 cases, 12 cases of obesity. 1.2 Methods 66 patients with gastroesophageal reflux disease were randomly divided into groups and omeprazole rabeprazole group. Rabeprazole group, 34 patients to rabeprazole 10 mg, 2 times a day, morning and evening, taking half an hour before a meal; Ogilvy amp; Mather pull-yl group of 32 patients to omeprazole 20 mg, 2 times a day for 8 weeks. medication during the exclusion bad food (tea, coffee, chocolate, high fat food such as interference. endoscopy were performed before treatment in both groups examination, endoscopy after 8 weeks of treatment review. 1.3 determine the efficacy of 1.3.1 symptom score rating 0: asymptomatic, 0, grade: occas